Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Juniperus virginiana pollen is an allergenic extract derived from the pollen of the Eastern Red Cedar tree (Juniperus virginiana). It is approved in the United States for use in allergen immunotherapy to treat allergic conditions such as allergic rhinitis (hay fever) caused by sensitivity to this specific pollen. The treatment works by gradually desensitizing the patient's immune system to the pollen's allergens, thereby reducing the allergic response. The active components include allergenic proteins like Jun v 1 and Jun v 3. Multiple companies, including Stallergenes Greer, manufacture this extract, which is available for both human and veterinary use. [4]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on juniperus virginiana pollen.